Carmelo Nucera, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 29 | 2023 | 2282 | 4.980 |
Why?
|
| Proto-Oncogene Proteins B-raf | 18 | 2023 | 2043 | 2.530 |
Why?
|
| Pericytes | 5 | 2023 | 292 | 2.410 |
Why?
|
| Indoles | 8 | 2015 | 1839 | 1.070 |
Why?
|
| Carcinoma | 6 | 2016 | 2375 | 1.070 |
Why?
|
| Sulfonamides | 8 | 2015 | 1938 | 0.990 |
Why?
|
| Neovascularization, Pathologic | 6 | 2021 | 2635 | 0.800 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2021 | 78 | 0.770 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2021 | 188 | 0.760 |
Why?
|
| Phenylurea Compounds | 2 | 2021 | 528 | 0.710 |
Why?
|
| Lipogenesis | 1 | 2021 | 212 | 0.680 |
Why?
|
| Mutation | 13 | 2022 | 29786 | 0.650 |
Why?
|
| RNA, Untranslated | 1 | 2021 | 453 | 0.600 |
Why?
|
| Quinolines | 1 | 2021 | 732 | 0.570 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2018 | 315 | 0.550 |
Why?
|
| Thrombospondin 1 | 2 | 2023 | 250 | 0.530 |
Why?
|
| Genes, p16 | 1 | 2015 | 157 | 0.520 |
Why?
|
| Genes, p53 | 2 | 2015 | 755 | 0.520 |
Why?
|
| Gene Dosage | 3 | 2015 | 1252 | 0.510 |
Why?
|
| Angiogenic Proteins | 1 | 2015 | 104 | 0.510 |
Why?
|
| Iodine | 1 | 2016 | 286 | 0.490 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2018 | 644 | 0.490 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2021 | 5172 | 0.480 |
Why?
|
| Hemangiopericytoma | 1 | 2014 | 77 | 0.480 |
Why?
|
| Frameshift Mutation | 1 | 2015 | 399 | 0.460 |
Why?
|
| Micronutrients | 1 | 2016 | 375 | 0.460 |
Why?
|
| Cachexia | 1 | 2015 | 204 | 0.460 |
Why?
|
| Mutagenesis, Insertional | 1 | 2015 | 655 | 0.440 |
Why?
|
| Iodine Radioisotopes | 4 | 2023 | 1032 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 8428 | 0.370 |
Why?
|
| Parietal Lobe | 1 | 2015 | 838 | 0.370 |
Why?
|
| Antineoplastic Agents | 6 | 2021 | 13695 | 0.370 |
Why?
|
| Carcinoma, Papillary | 4 | 2022 | 783 | 0.360 |
Why?
|
| Disease Progression | 4 | 2018 | 13284 | 0.360 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2015 | 1142 | 0.350 |
Why?
|
| Energy Metabolism | 1 | 2021 | 2899 | 0.350 |
Why?
|
| Tumor Microenvironment | 5 | 2023 | 3586 | 0.340 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2009 | 170 | 0.330 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2021 | 3557 | 0.320 |
Why?
|
| Thyroid Hormones | 1 | 2010 | 390 | 0.310 |
Why?
|
| Mitochondria | 1 | 2021 | 3520 | 0.310 |
Why?
|
| Cell Line, Tumor | 10 | 2021 | 16689 | 0.300 |
Why?
|
| Disease Models, Animal | 7 | 2023 | 18029 | 0.300 |
Why?
|
| Leptin | 1 | 2015 | 1599 | 0.290 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 1889 | 0.280 |
Why?
|
| Thyroidectomy | 4 | 2015 | 879 | 0.270 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2015 | 2948 | 0.270 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 1213 | 0.260 |
Why?
|
| Embryonic Development | 1 | 2010 | 711 | 0.260 |
Why?
|
| Hyperhomocysteinemia | 1 | 2006 | 124 | 0.260 |
Why?
|
| Hypoparathyroidism | 1 | 2006 | 120 | 0.260 |
Why?
|
| Mice, SCID | 5 | 2015 | 2716 | 0.250 |
Why?
|
| Oncogene Proteins | 1 | 2009 | 749 | 0.250 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2006 | 284 | 0.250 |
Why?
|
| DiGeorge Syndrome | 1 | 2006 | 177 | 0.240 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2006 | 173 | 0.240 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 2038 | 0.240 |
Why?
|
| Transcriptional Activation | 1 | 2010 | 1783 | 0.240 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2023 | 5535 | 0.240 |
Why?
|
| Transfection | 4 | 2015 | 5892 | 0.230 |
Why?
|
| Galectin 3 | 1 | 2005 | 227 | 0.220 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 3703 | 0.220 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 3647 | 0.200 |
Why?
|
| Mutation, Missense | 1 | 2010 | 2564 | 0.200 |
Why?
|
| Mice | 12 | 2023 | 81183 | 0.190 |
Why?
|
| Valine | 2 | 2014 | 413 | 0.190 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 2942 | 0.190 |
Why?
|
| Signal Transduction | 6 | 2018 | 23403 | 0.190 |
Why?
|
| Cytokines | 1 | 2015 | 7322 | 0.180 |
Why?
|
| Immunohistochemistry | 5 | 2015 | 11366 | 0.180 |
Why?
|
| Neoplasm Metastasis | 2 | 2021 | 4851 | 0.160 |
Why?
|
| Humans | 32 | 2023 | 744343 | 0.150 |
Why?
|
| Animals | 14 | 2023 | 168757 | 0.150 |
Why?
|
| Glutamic Acid | 2 | 2014 | 1169 | 0.150 |
Why?
|
| Thyroid Gland | 4 | 2012 | 1173 | 0.140 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 2187 | 0.130 |
Why?
|
| Mass Spectrometry | 2 | 2014 | 2203 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2015 | 126 | 0.130 |
Why?
|
| Blotting, Western | 2 | 2015 | 5179 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2016 | 3508 | 0.130 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2015 | 643 | 0.120 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 8863 | 0.120 |
Why?
|
| Aphasia | 1 | 2015 | 179 | 0.120 |
Why?
|
| Adenoma | 1 | 2005 | 2174 | 0.120 |
Why?
|
| Databases, Genetic | 1 | 2021 | 1783 | 0.120 |
Why?
|
| Fatty Acids | 1 | 2021 | 1809 | 0.110 |
Why?
|
| Cell Proliferation | 4 | 2014 | 10481 | 0.110 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2012 | 177 | 0.100 |
Why?
|
| Craniotomy | 1 | 2015 | 729 | 0.100 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 1878 | 0.100 |
Why?
|
| Brain Edema | 1 | 2015 | 617 | 0.100 |
Why?
|
| Lac Operon | 1 | 2010 | 238 | 0.090 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 399 | 0.090 |
Why?
|
| Mice, Inbred DBA | 1 | 2010 | 642 | 0.090 |
Why?
|
| beta-Galactosidase | 1 | 2010 | 573 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2012 | 546 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2011 | 480 | 0.090 |
Why?
|
| Cell Movement | 2 | 2012 | 5217 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2011 | 489 | 0.080 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 9438 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 3870 | 0.080 |
Why?
|
| Models, Biological | 2 | 2018 | 9583 | 0.080 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 847 | 0.080 |
Why?
|
| Vision Disorders | 1 | 2015 | 1058 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2009 | 323 | 0.080 |
Why?
|
| Benzenesulfonates | 1 | 2009 | 169 | 0.080 |
Why?
|
| Genotype | 2 | 2014 | 12951 | 0.080 |
Why?
|
| Apoptosis | 3 | 2015 | 9727 | 0.080 |
Why?
|
| RNA Interference | 3 | 2012 | 2889 | 0.080 |
Why?
|
| Cell Survival | 2 | 2015 | 5882 | 0.080 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 553 | 0.070 |
Why?
|
| Isoquinolines | 1 | 2009 | 367 | 0.070 |
Why?
|
| Transgenes | 1 | 2010 | 1009 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 3920 | 0.070 |
Why?
|
| Niacinamide | 1 | 2009 | 417 | 0.070 |
Why?
|
| Genes, Reporter | 1 | 2010 | 1547 | 0.070 |
Why?
|
| Amino Acid Substitution | 1 | 2010 | 1791 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2016 | 3086 | 0.070 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 2085 | 0.070 |
Why?
|
| Phenotype | 2 | 2021 | 16365 | 0.060 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 1613 | 0.060 |
Why?
|
| Cell Line | 3 | 2013 | 15997 | 0.060 |
Why?
|
| Genetic Engineering | 1 | 2010 | 951 | 0.060 |
Why?
|
| RNA, Small Interfering | 2 | 2012 | 3505 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2009 | 1641 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2011 | 3002 | 0.060 |
Why?
|
| Central Nervous System | 1 | 2010 | 1357 | 0.060 |
Why?
|
| Thyroid Nodule | 1 | 2010 | 750 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2009 | 2649 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 2727 | 0.050 |
Why?
|
| Graves Disease | 1 | 2003 | 242 | 0.050 |
Why?
|
| Thyroid Diseases | 1 | 2005 | 379 | 0.050 |
Why?
|
| DNA Copy Number Variations | 1 | 2010 | 1941 | 0.050 |
Why?
|
| Prognosis | 1 | 2021 | 29063 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2005 | 2327 | 0.050 |
Why?
|
| Staining and Labeling | 1 | 2005 | 1100 | 0.050 |
Why?
|
| Female | 11 | 2022 | 380194 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2011 | 8436 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 17446 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2010 | 3617 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 5867 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2009 | 2915 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 3 | 2012 | 3616 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2009 | 5974 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 9734 | 0.040 |
Why?
|
| Pyridines | 1 | 2009 | 2825 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 9239 | 0.030 |
Why?
|
| Aged | 5 | 2015 | 163280 | 0.030 |
Why?
|
| Male | 7 | 2012 | 350118 | 0.030 |
Why?
|
| Adult | 6 | 2022 | 214055 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 21827 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2009 | 57776 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 2011 | 13102 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 1682 | 0.020 |
Why?
|
| Pregnancy | 1 | 2010 | 29144 | 0.020 |
Why?
|
| Sicily | 1 | 2008 | 8 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2010 | 411 | 0.020 |
Why?
|
| Middle Aged | 5 | 2012 | 213383 | 0.020 |
Why?
|
| Microdissection | 1 | 2008 | 152 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2012 | 2839 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2012 | 1012 | 0.020 |
Why?
|
| Random Allocation | 1 | 2011 | 2429 | 0.020 |
Why?
|
| Multigene Family | 1 | 2010 | 1102 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2012 | 19229 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2009 | 40561 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2012 | 3128 | 0.020 |
Why?
|
| Geography | 1 | 2008 | 669 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2010 | 1063 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2010 | 1094 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 1799 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2008 | 638 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 2503 | 0.010 |
Why?
|
| Lasers | 1 | 2008 | 952 | 0.010 |
Why?
|
| DNA Primers | 1 | 2008 | 2892 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2011 | 2967 | 0.010 |
Why?
|
| Cell Division | 1 | 2010 | 4568 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2012 | 4204 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 1434 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 2938 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 4186 | 0.010 |
Why?
|
| Wound Healing | 1 | 2012 | 2785 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2010 | 1859 | 0.010 |
Why?
|
| Neoplasms | 1 | 2010 | 21683 | 0.010 |
Why?
|
| Zebrafish | 1 | 2012 | 2994 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 4751 | 0.010 |
Why?
|
| Weight Loss | 1 | 2011 | 2622 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 13815 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2008 | 2924 | 0.010 |
Why?
|
| Protein Binding | 1 | 2012 | 9386 | 0.010 |
Why?
|
| Body Weight | 1 | 2010 | 4669 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 2728 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 18111 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 8642 | 0.010 |
Why?
|
| Patient Selection | 1 | 2010 | 4215 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2003 | 1486 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 11031 | 0.010 |
Why?
|
| Genomics | 1 | 2010 | 5720 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 13033 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 15519 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 39050 | 0.000 |
Why?
|
| Young Adult | 1 | 2012 | 56430 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2003 | 63114 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 2003 | 77449 | 0.000 |
Why?
|